Mesothelioma Staging

The TNM Staging System (Stages I–IV)

The TNM staging system is the internationally accepted standard for staging pleural mesothelioma. Developed by the American Joint Committee on Cancer (AJCC) and the International Association for the Study of Lung Cancer (IASLC), the TNM system evaluates three factors: the size and extent of the primary Tumor, whether cancer has spread to nearby lymph Nodes, and whether Metastasis (distant spread) has occurred. The current edition (AJCC 8th Edition) classifies pleural mesothelioma into four stages.

Stage I — Localized Disease

In Stage I, the cancer is confined to the pleural lining on one side of the chest. It has not spread to lymph nodes or distant organs. Stage I is subdivided into two categories:

• Stage IA — the tumor involves the parietal pleura (chest wall lining) only, without invasion of the visceral pleura (lung surface)
• Stage IB — the tumor involves both the parietal and visceral pleura on the same side of the chest

Stage I patients are the best candidates for curative-intent surgery, including extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D) as part of a multimodal treatment plan.

Stage II — Locally Advanced (Resectable)

In Stage II, the tumor has spread beyond the pleura into adjacent structures on the same side, but the disease remains potentially resectable:

• Tumor has grown into the lung tissue, the diaphragm, or the mediastinal fat on the same side
• Lymph nodes are not involved, or only ipsilateral (same-side) bronchopulmonary or hilar lymph nodes are affected
• No distant metastasis is present

Surgery remains an option for most Stage II patients, combined with chemotherapy and/or radiation to maximize disease control.

Stage III — Locally Advanced (Often Unresectable)

Stage III mesothelioma has spread more extensively within the chest but has not metastasized to distant organs. This stage encompasses a range of disease extent:

• Stage IIIA — tumor has grown into the chest wall, pericardium, or mediastinal structures and may involve ipsilateral mediastinal or internal mammary lymph nodes
• Stage IIIB — more extensive local invasion, including involvement of the spine, ribs, contralateral pleura, or brachial plexus; or contralateral or supraclavicular lymph node involvement

Surgery is possible in select Stage IIIA cases, but most Stage III patients are treated with systemic therapy — typically chemotherapy, immunotherapy, or a combination — along with palliative radiation as needed.

Stage IV — Metastatic Disease

In Stage IV, mesothelioma has spread to distant organs such as the liver, bones, brain, or the pleura on the opposite side of the chest. Treatment at this stage focuses on controlling the disease, managing symptoms, and improving quality of life:

• Immunotherapy (nivolumab + ipilimumab) is a first-line treatment option
• Chemotherapy (pemetrexed + cisplatin or carboplatin) for systemic disease control
• Palliative radiation for pain relief and symptom management
• Clinical trials may offer access to emerging therapies

Staging Tests & Diagnostic Imaging

Accurate staging requires a comprehensive workup using multiple imaging modalities and, in some cases, invasive procedures to assess lymph node involvement. The staging workup determines the extent of the disease and directly informs treatment planning. Staging should be performed at a specialized mesothelioma treatment center where physicians have experience interpreting the imaging findings for this rare cancer.

Imaging Studies Used in Staging

• CT Scan (Computed Tomography) — the primary staging tool for mesothelioma. High-resolution CT scans of the chest and abdomen provide detailed images of tumor location, size, pleural thickening, pleural effusion, and involvement of adjacent structures including the chest wall, diaphragm, and mediastinum. CT is essential for surgical planning and assessing resectability.
• PET Scan (Positron Emission Tomography) — PET scans use a radioactive glucose tracer (FDG) to detect metabolically active cancer cells throughout the body. PET is critical for identifying whether the cancer has spread to lymph nodes or distant organs. PET-CT fusion imaging combines the metabolic information from PET with the anatomical detail of CT for the most accurate staging assessment.
• MRI (Magnetic Resonance Imaging) — MRI provides superior soft-tissue contrast compared to CT and is particularly useful for evaluating diaphragm invasion, chest wall involvement, and tumor extent near the spine or major blood vessels. MRI is often used in addition to CT and PET when surgical resection is being considered.

Invasive Staging Procedures

• Mediastinoscopy — a small incision is made at the base of the neck, and a scope is inserted to biopsy mediastinal lymph nodes. This procedure helps determine whether cancer has spread to the central lymph nodes of the chest, which is critical for assessing surgical eligibility.
• Endobronchial Ultrasound (EBUS) — a bronchoscope with an ultrasound probe is used to visualize and biopsy lymph nodes adjacent to the airways. EBUS is a less invasive alternative to mediastinoscopy for lymph node staging.
• Thoracoscopy (VATS) — in addition to obtaining tissue for diagnosis, thoracoscopy allows the surgeon to directly visualize the pleural surfaces and assess the extent of tumor involvement, providing valuable staging information that may not be visible on imaging alone.

Why Staging Matters for Legal Claims

Accurate mesothelioma staging is not only critical for treatment planning — it also plays a significant role in legal claims and compensation. The stage at diagnosis affects every aspect of a legal case, from the urgency of filing to the potential value of the claim.

How Staging Impacts Your Legal Case

• Establishing disease severity — staging documentation provides objective medical evidence of the extent and seriousness of the disease. Advanced-stage diagnoses demonstrate greater harm, which supports higher damage awards for medical expenses, lost income, pain and suffering, and reduced life expectancy.
• Statute of limitations urgency — every state has a deadline for filing mesothelioma claims. Because advanced-stage patients have shorter life expectancies, it is critical to consult with a mesothelioma attorney immediately after diagnosis to preserve all legal options. Some courts allow expedited trial schedules for patients with advanced disease.
• Treatment cost documentation — staging determines the treatment plan, which directly affects the total medical costs. A Stage I patient undergoing multimodal surgery, chemotherapy, and radiation may face $500,000 or more in medical costs. These documented costs are a key component of compensation calculations.
• Trust fund claim amounts — asbestos trust funds use medical documentation, including staging, to evaluate and process claims. Thorough staging records help ensure claims are processed efficiently and at appropriate payment levels.
• Wrongful death and survival claims — if a patient passes away, the staging documentation at diagnosis supports wrongful death claims by establishing the disease progression, the medical interventions required, and the impact on the patient's quality and length of life.